GLP1R and metabolic dysfunction-associated steatohepatitis: This study indicates that the therapeutic advantages of GLP‐1 receptor agonists in metabolic‐associated steatotic hepatitis (MASH) are predominantly indirect, facilitated by enhancements in systemic metabolism—specifically, weight reduction, glycemic regulation and insulin sensitization—which subsequently foster a hepatic environment favourable for recovery (decreased lipogenesis, improved fat utilisation and diminished inflammation).